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A 41-year-old female presented to the hospital with sore throat and shortness of breath. She was hypoxic with an oxygen saturation
of 87% in room air. Physical examination revealed swollen uvula with exudates. She had been started on topiramate for treatment
of migraine few months ago. The dose of topiramate was increased to 100 mg twice daily 2 weeks ago. Complete blood count
revealed an absolute neutrophil count (ANC) of 8 c/mm3. She was intubated and started on broad-spectrum antibiotics. She was
transferred to our hospital on the fifth day of hospitalization. On arrival, her absolute neutrophil count was 10 c/mm3. Her
agranulocytosis was attributed to topiramate after ruling out other possible causes. ANC improved after topiramate was stopped.
ANC increased to 1000 after 5 days of stopping topiramate. We also reviewed published cases of topiramate-associated
agranulocytosis. Agranulocytosis is a rare side effect of topiramate, and only 3 case reports have been published so far. In all
cases, agranulocytosis developed after months of topiramate therapy and when dose was increased to 200 mg daily suggesting
a dose-dependent effect. Next steps would be further research on the pathogenesis of agranulocytosis associated with topiramate
and creation of registry for data synthesis.

1. Introduction
Topiramate is a novel anticonvulsant with multiple mechanisms of action including inhibition of voltage-activated
sodium and calcium channels, augmentation of GABA receptors, and inhibition of carbonic anhydrase [1]. It is used to
treat focal as well as generalized seizures. In addition, it is FDA
approved for migraine prophylaxis and weight loss pharmacotherapy in combination with phentermine [1]. The main
side effects of topiramate include cognitive slowing, wordfinding difficulty, and impaired executive function [2]. Other
common adverse effects are sedation and weight loss [2].
Agranulocytosis is severe reduction in neutrophil count less
than 500 cells/mm [3, 4]. Agranulocytosis is drug induced
in 70% of cases [5]. Some of the commonly associated drugs
include clozapine, diclofenac, carbamazepine, vancomycin,
trimethoprim/sulfamethoxazole, beta-lactam antibiotics,
levamisole, and ticlopidine [5]. Agranulocytosis is a rare
side effect of topiramate. In our article, we describe a case
of agranulocytosis associated with topiramate and then

review cases of agranulocytosis or leucopenia associated
with topiramate.

2. Case Report
A 41-year-old female with a past medical history of Sjogren
syndrome, asthma, migraines, and generalized seizures well
controlled with medications was admitted to the intensive
care unit after transfer from an outside hospital. She had
presented to the outside hospital 5 days ago with sore throat,
trouble speaking, and shortness of breath. Her family noticed
that, over the last several days, she had been more confused
and brought her to the emergency department for evaluation.
On presentation, she was hypoxic with an oxygen saturation
level of 87% in room air, temperature of 101.2 F, pulse of
110/minute, and blood pressure of 100/60 mmHg. Physical
examination revealed swollen uvula without exudates. Because of her mental status and hypoxia, she was intubated and
transferred to the outside hospital’s intensive care unit for
further care. The rest of the physical examination was within
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normal limits. On review of her medications, it was found that
she had been treated with Plaquenil on an outpatient setting
which was discontinued a month ago. She was started on
topiramate for treatment of migraine by her neurologist few
months ago. The dose of the topiramate had been increased to
100 mg twice a day 2 weeks ago. Rest of her medications
included tramadol as needed and an albuterol inhaler.
Complete blood count revealed an absolute neutrophil count
(ANC) of 8 c/mm3. Blood and throat cultures were sent, and
she was started on broad-spectrum antibiotics, including
vancomycin, piperacillin-tazobactam, and clindamycin.
Streptococcus pyogenes and Hemophilus influenzae were isolated from throat, and her blood culture was found to be
positive for Escherichia coli.
When she arrived at our hospital on her hospital day 5,
she was still intubated. Her ANC was 10 c/mm3. Labs were
significant for negative polymerase chain reaction (PCR) for
Epstein–Barr virus (EBV), cytomegalovirus (CMV), human
immunodeficiency virus (HIV), hepatitis B virus (HBV), and
hepatitis C virus (HCV). The vitamin B12 level was 600 ng/L
(normal 180–914 ng/L). The folate level in blood was
12 ng/mL (normal 2–20 ng/mL). Flow cytometry of peripheral blood leucocytes showed T-cell population (about
50% of the cells analyzed) with no aberrant loss or aberrant
expression of T-cell markers, a B-cell population (about 45%
of the cells analyzed) that was negative for CD5 and CD10,
and no surface light-chain restriction. The analyzed cells
were negative for CD34, CD13, and CD33. Hematology
services was consulted which did not think her agranulocytosis was due to primary bone marrow problem and
recommended no need for bone marrow biopsy. Topiramate
had been held from hospital day 1. Broad-spectrum antibiotics were continued. She also received 1 dose of granulocytemonocyte colony-stimulating factor (GM CSF) on hospital
day 6. Her neutrophil count started improving, and ANC was
1000 on the eleventh day of hospitalization.

3. Discussion
In our case, the probability of causal relationship of agranulocytosis and topiramate was assessed by the WHO-UMC
algorithm [6]. Because the low numbers of ANC did return
towards normal levels under continuous treatment, the
probablility that the agranulocytosis related to topiramate can
be rated only as probable.
In spite of the lack of evidence of efficacy in drug-induced
neutropenia [7], granulocyte-monocyte colony-stimulating
factor (GM CSF) is used empirically at doses of 5 mcg/kg
per day. Treatment with GM CSF can be discontinued when
the total white blood cell count exceeds 10,000/microL [8]. In
our case, it was not clear why she received a single injection of
GM CSF rather than daily injections.
Search done for cases of agranulocytosis/neutropenia/
leucopenia associated with topiramate in major databases
MEDLINE, Embase, and Cochrane Library revealed three
case reports [9–11].
In the case reported by Minakawa et al. [10], a 40-year-old
male with intractable frontal lobe epilepsy was started on
topiramate 100 mg daily, eventually increased to 200 mg/day
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over 2 weeks. Other concurrent medications included phenytoin and acetazolamide. He was found to have an absolute
neutrophil count of 440/mm3 on day 38 of topiramate
therapy. It was not mentioned whether the patient developed
any symptoms or signs from agranulocytosis. Topiramate
was decreased to 100 mg/day and discontinued after a week
of agranulocytosis. He was on phenytoin during the entire
period. No further tests to rule out possible causes of
agranulocytosis were done as there was no reduction in
hemoglobin and platelets, and agranulocytosis resolved 5 days
after stopping topiramate.
Behar and Schaller [9] reported a case of a 28-year-old
male with a past medical history of bipolar disorder on
clozapine therapy who had topiramate added as a mood
stabilizer after the patient’s mother was concerned about his
weight gain on clozapine therapy. His white blood cell
(WBC) count had been stable on clozapine for 2 years.
Topiramate was added 25 mg twice a day for 1 week, 50 mg
twice a day for 1 week, 100 mg twice a day for 1 week, and
then 200 mg twice a day. He was followed with complete
blood count every 2 weeks. He developed leucopenia
(WBC count of less than 4000/mm3) after 1 week of topiramate
200 mg twice a day. His WBC count was 3700/mm3 after
a week. Clozapine was stopped at that time. His WBC dropped
to 3700/mm3 on the seventeenth day and 3100/mm3 on day 22
of topiramate therapy of 200 mg twice daily. He started having
manic symptoms after clozapine was stopped. His family
withdrew objection to weight gain, and topiramate was
stopped. He was restarted on clozapine. His WBC count
was 11,500/mm3 a week off topiramate and on clozapine.
His manic symptoms resolved.
Sharma et al. [11] reported a case of a 23-year-old male
with diagnosis of paranoid schizophrenia on clozapine
therapy at a dose of 300 mg daily. He was started on topiramate due to concern for weight gain on clozapine therapy.
Topiramate was started at 25 mg daily for a week, 50 mg daily
for 2 weeks, and then 100 mg daily. He continued clozapine
300 mg/day and topiramate 100 mg/day for eight months
during which time his white cell count remained under
normal limits. After eight months, topiramate was increased
to 200 mg per day as he was still gaining weight. The patient’s
dose of clozapine was not changed. On the 57th day of
therapy, with topiramate 200 mg daily along with clozapine
300 mg/day, his absolute neutrophil count was 1200/mm3.
Clozapine was discontinued. It was not mentioned whether
he developed any clinical features from reduction in neutrophils. After 2 days of stopping clozapine, topiramate was
tapered off. He was started on olanzapine and lithium
therapy. ANC returned to normal limits. It was not clear
how long it took for ANC to return to normal after stopping
topiramate. This case is less clearly related to topiramate as
clozapine also may cause agranulocytosis.
Agranulocytosis is a rarely reported side effect of topiramate, and its true incidence is unknown. Few cases have
been reported in the medical literature. In a systematic
review published by Andersohn et al. [4], 980 cases of
nonchemotherapy drug-induced agranulocytosis from
1966 to 2006 were reported. There was not a single case of
topiramate-associated agranulocytosis in the systematic review.
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However, sulfonamides including carbonic anhydrase inhibitors to which topiramate also belongs to are among the
most commonly reported drugs for causing hematological
disorders [12].
Drug-induced agranulocytosis can occur via multiple
mechanisms. Two of the most commonly cited mechanisms
include immunogenic effects (via generation of an oxidative
metabolite that stimulates T cells to attack the marrow) and
direct toxicity of the drug to the bone marrow [7]. The
pathogenesis of agranulocytosis associated with topiramate
is not clear. In cases of immune-mediated neutropenia/
agranulocytosis, neutrophil count usually drops rapidly
within 5 to 7 days of drug administration [3]. Immunemediated agranulocytosis is often accompanied by rash and
fever as seen in cases of agranulocytosis associated with betalactam antibiotics, which was not seen in our case or any of
the reviewed cases [3]. Topiramate (sulfamate) is structurally
similar to sulfones (dapsone) and sulfonamides (acetazolamide,
sulfonylureas, and sulfamethoxazole). Dapsone causes agranulocytosis due to the toxic action of its metabolites against
neutrophils and bone marrow [13]. In our case as well as in the
other reported cases, reduction in neutrophil count was detected after months of topiramate therapy. In the reported
cases, neutrophil count decreased when the dose of topiramate
was increased to 200 mg daily, suggesting a dose-dependent
effect. No reduction in neutrophil count was seen with doses
less than 200 mg daily [11]. These all suggest that topiramateassociated reduction in neutrophil count is most likely secondary to toxic effects of the drug. However, further research is
required in future to elucidate the mechanism of topiramateassociated agranulocytosis.

4. Conclusion
Topiramate is a broad-spectrum novel anticonvulsant used
for seizure treatment, migraine prophylaxis, and weight loss.
Agranulocytosis/neutropenia is a rare side effect of topiramate and is limited to few case reports. The pathogenesis
of reduction in neutrophil count associated with topiramate
is not entirely known. In our case as well as in other
published cases, reduction in neutrophil count occurred
after months of topiramate therapy and at doses greater than
or equal to 200 mg daily. In all cases, neutrophil count
returned to normal after topiramate was stopped. Next steps
would be further research on the pathogenesis of agranulocytosis associated with topiramate and creation of registry
for data synthesis.
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